

Structural and Functional Brain Alterations in Post-Chemotherapy Cognitive Impairment in Gastric Cancer: A Longitudinal Multimodal Neuroimaging Study

Jaeun Ahn

Yonsei University College of Medicine

DeokJong Lee

Yonsei University College of Medicine

Young-Chul Jung

Yonsei University College of Medicine

KYUNG RAN KIM (✉ drgreat@yuhs.ac)

Yonsei University College of Medicine <https://orcid.org/0000-0001-8375-1851>

Research article

Keywords: Chemobrain, Chemotherapy-induced cognitive impairment, gastric cancer, neuroimaging, fMRI, resting state functional connectivity, DTI, VBM

Posted Date: July 21st, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-44806/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Backgrounds: Despite clinical significance of chemobrain, no longitudinal study has been made on change in cognitive function related to chemotherapy in gastric cancer. The aim of this study is to define structural and functional changes in brains of gastric cancer patients caused by chemotherapy-induced cognitive impairment after adjuvant chemotherapy.

Methods: 13 gastric cancer patients with adjuvant chemotherapy (CTx+ group), 9 gastric patients without adjuvant chemotherapy (CTx- group), and 10 healthy controls (HC) were enrolled for this study. We performed self-report questionnaires, neurocognitive tests, voxel-based morphometry (VBM), hippocampus-seeded resting-state functional magnetic resonance imaging (rsfMRI) and diffusion tensor imaging (DTI) analysis twice at before and 3 months after chemotherapy.

Results: Compared to CTx- group, CTx+ group exhibited statistically significant decrease in attention and executive function over time, and also exhibited dysfunction in delayed recognition performance. Results in resting state functional connectivity analysis show significant group-by-time interaction in left hippocampus-anterior thalamus. In addition, DTI analysis had interesting results that showed reduced fractional anisotropy (FA), and increased mean diffusivity (MD) in left hippocampus. However, results from VBM analysis confirms that chemotherapy does not cause structural changes in brain.

Conclusion: To the best of our knowledge, this is the first longitudinal neuroimaging study on the effect of chemotherapy in gastric cancer patients. Based on the results of this study, we suggest that neuropathological processes and clinical presentation of chemobrain is ultimately similar disease as age-related neurodegenerative disorder. Results of this study help in viewing underlying basis of chemobrain at a new angle and puts emphasis in importance of continuous assessment and intervention.

Background

Chemotherapy-induced cognitive impairment, also referred to as chemobrain, is one of the most frequently reported side effects of chemotherapy and is an important dysfunction that is directly related to impaired social and occupational function and decreased quality of life (1). After chemotherapy, 18%-78% of cancer patient experience cognitive impairment such as memory loss, apraxia, attention deficit, etc (2, 3). These symptoms may disappear in the short-term, but as many as 35% of chemotherapy patients suffer from continued symptoms even after months or years after complete recovery of cancer (3–5). In addition, considering that chemotherapy-induced cognitive impairment can increase the risk of dementia and stroke (6, 7), early detection of chemobrain is very important, clinically.

As clinical significance of Chemobrain phenomenon is highlighted, related research is increasing, but nevertheless, because well-designed prospective studies are limited (8), precise structural and functional changes in the brain that underlie this dysfunction is also still uncertain. Although limited in numbers, studies using structural neuroimaging technique and functional neuroimaging technique have helped us in understanding neural changes related to chemobrain in detail. Results of previous studies have

revealed that objective, neuroimaging tests detect clear neural changes associated with chemobrain. And it seems chemotherapy has neurotoxic effect on frontal, temporal and parietal regions similar in age-related neurodegenerative disorders (8). Beyond this, little is known with certainty. Majority of structural imaging studies using techniques such as voxel-based morphometry (VBM) and diffusion-tensor imaging (DTI) suggest that chemotherapy causes white and gray matter volume decrements and altered white matter microstructure (9–12). However, there is some disagreement concerning the duration of chemotherapy-induced structural changes (8). Looking into functional imaging researches, we can find limited task-based fMRI researches; However, despite resting state fMRI being a powerful tool in studying functional brain network, no longitudinal evaluation of resting state fMRI on decline of cognitive function after chemotherapy has been carried out up to now (8). The results of fMRI studies so far have reported hypoactivation or hyperactivation in many different areas of brain, but the results thus far have only reported inconsistent changes in functional connectivity (6). Considering ambiguity of results from past studies, it is of great clinical significance to study structural and functional neural change in brains of patients suffering from cognitive impairment symptom chemotherapy's neurotoxicity.

Although the neuropathological mechanisms underlying chemobrain is yet to be understood clearly, there have been evidences suggesting that hippocampus may be an important area that is vulnerable to chemotherapy-induced neurotoxicity in recent studies (13). In various previous rodent researches, evidences proving that chemobrain is related to impaired neurogenesis of hippocampus (14, 15), neuroinflammation(16, 17), oxidative stress, mitochondrial dysfunction(18, 19), and structural damage to neurons have been cumulating. Several recent neuroimaging studies have reported reduced total volume and inward deformities in hippocampal subfields in breast cancer patients (20, 21). Hippocampus is also a key area in cognitive function such as memory formation, learning(22), spatial processing(23), memory recognition, prospective memory processing(24), etc.. Furthermore, hippocampus was once understood as a single structure, but recently it has been emphasized that hippocampus is not a homogenous structure, but a domain consisting of several subfields with different histological characteristics and function(25). However, there is a need for research on the structural and functional changes of hippocampus in chemobrain, considering that they remain unknown.

Most of studies on chemobrain until now not only have been carried out on breast cancer patients due to reasons such as high survival rates of breast cancer, and potentially higher likelihood of female patients to report perceived changes in cognitive abilities (26, 27). However, based on the fact that the chemobrain phenomenon is not limited to breast cancer (28), we planned to study gastric cancer patients. Globally gastric cancer is major cause of morbidity and mortality with increasing number of total incident cases (29). Especially in South Korea, gastric cancer is the most prevalent cancer in male of age 35 to 65 (26) with the 5-year survival rate of around 71.5%, it is important to consider life after cancer of these patients (27). In addition, because incidence age of gastric cancer is getting lower (30), cognitive function after chemotherapy is becoming more important in order for patients to maintain social and occupational function. Furthermore, since it is still unclear whether chemobrain phenomenon is a side effect of chemotherapy or reflect a more general comorbidity of cancer (31, 32), gastric cancer is well suited to study chemobrain phenomenon because while brain metastases from breast cancer are second in line

after lung cancer (13–19%) (33), brain metastases in gastric cancer is exceedingly rare and diagnosed in < 1% of affected patients (34). Despite such phenomenon, no longitudinal study has been made until now on change in cognitive function related to chemotherapy in gastric cancer. From this point of view, research on gastric cancer patients help us understand which domain of cognitive function is affected and which neural changes are caused by chemotherapy, and therefore has great clinical significance for gastric cancer patients.

In this study, we aimed to study comprehensive underlying mechanism of chemobrain through multimodal neuroimaging analysis including VBM, rsfMRI and DTI. Firstly, we attempted to identify whether there is chemobrain underlying structural brain change through gray matter changes in VBM analysis. Secondly, we apply a hippocampus seed based resting state functional connectivity analysis to investigate neural network changes in chemobrain. we designated the bilateral hippocampus as the seed region in our study. Recently, there has been an accumulation of evidence that hippocampus is divided into several subfields, and each has a specific cognitive function. In particular, it is argued that neurodegenerative disorder patients show the sequential pattern of change in brain starting within entorhinal and transentorhinal areas and moving to cornu ammonis area 1 (CA1), subiculum and eventually other subfields. To study acute neurotoxic effect of chemotherapy, we conducted further analysis by classifying 6 subfields of hippocampus and setting them as seed region. Lastly, we attempted to identify how functional change is related to change in white matter microstructural integrity through DTI analysis. Until now, no other longitudinal DTI studies of white matter chemotherapy-induced changes have been performed for gastric cancer patient. Anticancer agents are known to cause extensive damage in myelin which is hallmark of WM tracts in experimental research (35).

As mentioned above, this study aims to achieve in depth understanding of cognitive impairments underlying neural change of gastric cancer patients after chemotherapy through longitudinal study using various multimodal neuroimaging techniques. To the best of our knowledge, this longitudinal research is the first research aiming to identify chemobrain underlying structural and functional changes in gastric cancer patients with focus on hippocampus using neuroimaging techniques.

Methods

Subjects

This prospective study was approved by the Institutional Review Board of Severance Hospital, and informed written consent was obtained from all subjects before each procedure. Male gastric cancer patients between age 40 and 60 who underwent total gastrectomy or partial gastrectomy (distal gastrectomy, subtotal gastrectomy) were enrolled in this study. Candidates were divided into two groups: patients with scheduled adjuvant chemotherapy (CTx+ group) and patients who do not need adjuvant chemotherapy (CTx- group). In addition, Age- and sex-matched healthy controls (HC group) without cognitive impairment or active neurological disorders were also recruited as a control group. Participants who had (1) history of other malignancy, (2) history of metastatic malignancy, (3) history of any

neurologic condition that could impair cognitive function (neurodegenerative disease, stroke, brain injury, etc.), (4) history of any neurologic condition that could impair cognitive function (dementia, stroke, brain injury, etc.), (5) history of alcohol, nicotine, caffeine, or other drug dependence or addiction and (6) psychiatric Axis I disorder were excluded in this study.

Initial baseline assessment was performed on CTx+ group (n = 19, age 49.2 ± 5.5) and CTx- group (n = 14 age 49.2 ± 6.8) and HC group (n=10, age 51.5 ± 7.0). Baseline assessment was performed by carry out self-report questionnaires assessment, neurocognitive assessment, and magnetic resonance imaging (MRI) scan all on the same day, after gastric cancer surgery and before adjuvant chemotherapy. In CTx+ group, follow-up assessment was performed around 3 months past baseline assessment, after the subject underwent adjuvant chemotherapy. CTx- group was also assessed on matched intervals.

Self-report questionnaires and neurocognitive assessment

Self-report questionnaires contained the Cognitive Failure Questionnaire (CFQ) (36) to assess subjective cognitive decline; the Beck Depression Inventory (BDI) (37) to assess depressive symptoms; and the Beck Anxiety Inventory (BAI) (38) to assess anxiety symptoms. All subjects carried out Structured Clinical Interview, and assessment on major psychiatric illness was performed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (39). Four cognitive domains were assessed using a set of neurocognitive tests: (1) performance and verbal intelligence [Korean version of Wechsler Adult Intelligence Scale (K-WAIS) performance and verbal subtests]; (2) memory (Rey-Kim Memory Test); (3) attention (K-WAIS digit span and spatial span subtest); and (4) executive function (stroop Test). Scores for the neurocognitive tests were expressed as age corrected scaled scores (AgeSS), standardized scores (SS), or percentile ranks for raw scores.

Image acquisition

All subjects were imaged on a 3.0 T MRI scanner (Tim Trio, Siemens Healthcare, Erlangen, Germany) and images including T1-weighted imaging, DTI and resting state fMRI were obtained. A 3D T1-weighted anatomical image was obtained using a spoiled gradient-echo sequence (sagittal acquisition with TR = 1900 msec; TE = 2.52 msec; FOV = 256×256 mm²; voxel size = $1 \times 1 \times 1$ mm³; flip angle 9°; slice number = 176; and total acquisition time 4 min 26 sec) to serve as an anatomical underlay for the brain activity and to be used for GM volume analysis. DTI were acquired with the following echo planar acquisition parameters: diffusion-weighted gradients applied in 30 non-linear directions, number of average = 2, TR = 6200 ms, TE = 85 ms, flip angle = 90°, acquisition matrix = 128×128 , FOV = 230×230 mm², slice thickness = 3 mm, and b value = 600 s/mm². Resting state functional images were acquired using gradient echo-planar pulse imaging (EPI). For each subject, 150 axial volume scans were obtained with the following parameters: TR = 3000 msec, TE = 30 msec, FOV = 192×192 mm², voxel size = $3 \times 3 \times 3$ mm³, slice number = 50 (interleaved). All participants were instructed to rest and keep their eye closed without sleeping, moving, or thinking about anything during the scan (7min 30sec). Vacuum-molded cushions and soft pads were used to support the head and minimize head movement.

Voxel-wise analysis of GM

All preprocessing steps were conducted in accordance with the standardized procedure (40). First, the structural images were aligned along the anterior–posterior commissure line and positioned so that the anterior commissure matched the origin. Afterward, the images were segmented into gray matter, white matter and cerebrospinal fluid probability maps by using a Bayesian image segmentation algorithm. Brain tissue probability maps for each subject were then used for intersubject alignment. In this study, we applied diffeomorphic anatomical registration by using an exponentiated Lie algebra algorithm (DARTEL) (40). The DARTEL has been suggested to enhance the accuracy of intersubject alignment, by modeling the shape of each brain by using a host of parameters. The DARTEL processing involves generating the flow fields that parameterize the deformations and creating the templates for all subjects. After the final study-specific template was created, gray matter images for each subject were warped to the study-specific template and then normalized into standard Montreal Neurological Institute space. The volumes were resampled to $1.5 \times 1.5 \times 1.5 \text{ mm}^3$ voxel size. This spatial normalization step included Jacobian modulation in order to preserve regional volume data. Finally, the DARTEL-warped, normalized and modulated gray matter images were smoothed by using 8-mm full-width at half maximum kernel.

Functional connectivity analysis

Spatial preprocessing and statistical analyses of functional images were performed using SPM12 (Wellcome Trust Centre for Neuroimaging). To analyze functional connectivity of resting state functional MRI, motion artifacts were assessed in individual subjects by visually inspecting realignment parameter estimations to confirm there were no abrupt head motions and the maximum head motion in each axis was $<3 \text{ mm}$. Functional images were realigned and registered to structural images for each subject. The anatomical volume was segmented into gray matter, white matter, and cerebrospinal fluid. The gray matter image was used for determining the parameters of normalization onto the standard Montreal Neurological Institute (MNI) gray matter template provided with SPM12. The spatial parameters were then applied to the realigned functional volumes that were finally resampled to voxels of $2 \times 2 \times 2 \text{ mm}^3$ and smoothed with an 8 mm full-width at half-maximum kernel.

The assessment of cortical networks was performed using a ROI seed-based correlation approach. Connectivity analysis was conducted with the “conn” toolbox, implemented in the SPM12 (<http://www.fil.ion.ucl.ac.uk/spm/ext>). Initially, the bilateral hippocampus seed regions were defined as MNI space taken from the AAL atlas(41). ROI for subfields of bilateral hippocampus (consisting of cornu ammonis(CA), including CA1,CA2, and CA3 subfields; dentate gyrus(DG), including fascia dentata and the CA4 subfield; and subiculum(SB), including the prosubiculum, subiculum proper,presubiculum and parasubiculum) was obtained from the the maximum probability map(MPM) (42) and was defined using the Anatomy toolbox v22c implemented on SPM12 (www.fil.ion.ucl.ac.uk/spm). The waveform of each brain voxel was temporally filtered by means of a bandpass filter ($0.008 \text{ Hz} < f < 0.09 \text{ Hz}$) to adjust for low-frequency drift and high-frequency noise effects. A linear regression analysis was conducted to remove signals from the ventricular area and the white matter(43). Movement parameters were added as

first-level covariate. The between-group, within-group longitudinal comparisons, and group-by-time interactions analyses were compared with an uncorrected p-value height threshold of 0.001 and $k=90$ as extent threshold for the whole brain. To estimate the strength of an FC, correlation coefficients were computed and converted to z-values using Fisher's r-to-z transformation.

DTI imaging processing and analysis

DTI data were analyzed using diffusion MR toolbox 'Explore DTI' (44) and following steps were performed: (i) correction for subject motion and eddy current induced distortions (45); (ii) tensor estimation using the REKINDLE approach for outlier detection (46) with iteratively reweighted linear **least squares** estimation after identification and removal of data outliers (47); and (iii) automated atlas based analysis with the SRI24 Atlas (normal adult brain anatomy; (48) using affine and elastic registration based on 'elastix' (49). All DTI data were visually checked in terms of quality of tensor estimation and quality of registration. After these preprocessing steps, FA, AD, RD, and MD values were calculated in the 130 brain regions that are provided by the SRI24 Atlas (48).

Statistical analysis

Baseline demographic characteristics including age, years of education and results from self-report questionnaires were compared between gastric cancer patients with one-way ANOVA. In analyzing results from neurocognitive assessment, we compared changes in performance status of neurocognitive test before and 3 months after adjuvant chemotherapy with a repeated measures ANOVA for a significance level of $P = 0.05$ between CTx+ group and CTx- group. Statistical analyses were conducted by using SPSS 25.0 (IBM, Armonk, NY, USA).

Results

Demographic characteristics

At baseline, 19 gastric cancer patients who underwent total gastrectomy or subtotal gastrectomy and were candidates for adjuvant chemotherapy and 14 patients who underwent total gastrectomy or partial gastrectomy (distal gastrectomy, subtotal gastrectomy) but not adjuvant chemotherapy were enrolled in this study. Of the 19 patients who received adjuvant chemotherapy after surgery, 6 were excluded as 2 patients expired during chemotherapy and 4 refused follow-up assessment after chemotherapy. 5 patients who were enrolled in CTx- group were excluded as well because they refused follow-up assessment. Age-matched 13 healthy men were recruited as control subjects. Among them, 2 healthy control participants were excluded since they showed cognitive impairment on the neurocognitive tests. And 1 healthy control participant excluded due to fail to perform multimodal neuroimaging studies. No participant was excluded due to excessive head movement during fMRI scanning. Therefore, the final sample size for the longitudinal analysis was total of 38, and all subjects had completed formal education. The breakdown of sample size is as follows: 13 for the CTx + group, 9 for the CTx- group, and 10 for the control group (Fig. 1).

CTx + group consisted of 1 cancer stage I patient, 3 cancer stage II patients, 8 cancer stage III patients, and 1 cancer stage IV patient, and went through XELOX or TS-1 regimen chemotherapy. CTx- group consisted of 3 cancer stage I patients, and 6 cancer stage II patients. Implemented surgery type, protocol of adjuvant chemotherapy and cancer stages of patients are summarized in Table 1. At baseline, there was no significant difference between the two groups in terms of age, duration of education, CFQ score, BDI score and BAI score (Table 2).

Table 1
Clinical characteristics of gastric cancer patients

| | CTx + (n = 13) | CTx - (n = 9) |
|---|----------------|---------------|
| Surgery type | | |
| Total gastrectomy | 4 | 0 |
| Subtotal gastrectomy | 8 | 2 |
| Distal gastrectomy | 1 | 7 |
| Cancer stage | | |
| I | 1 | 3 |
| II | 3 | 6 |
| III | 8 | 0 |
| IV | 1 | 0 |
| Protocol of adjuvant chemotherapy | | |
| XELOX | 7 | N/A |
| TS-1 | 6 | N/A |
| Notes: CTx+: Patients Treated with Chemotherapy; CTx-: Patients Not Treated with Chemotherapy; XELOX : oxaliplatin + Xeloda; TS-1 : Tagafur + Gemaracil | | |

Table 2
Demographic and clinical characteristics of gastric cancer patients and controls at baseline

| | CTx+ (n = 13) | CTx- (n = 9) | HC (n = 10) | F | <i>p</i> |
|---------------------------|----------------------|---------------------|--------------------|----------|-----------------|
| Age (years) | 49.2 ± 5.5 | 49.2 ± 6.8 | 51.5 ± 7.0 | 0.472 | 0.628 |
| Years of education | 13.1 ± 3.2 | 13.3 ± 2.0 | 12.7 ± 1.6 | 0.189 | 0.828 |
| BDI | 9.8 ± 7.4 | 8.2 ± 6.8 | 10.7 ± 6.9 | 0.366 | 0.696 |
| BAI | 6.0 ± 6.6 | 6.9 ± 5.4 | 6.2 ± 5.9 | 0.075 | 0.928 |
| CFQ | 9.5 ± 9.7 | 16.8 ± 11.0 | 19.8 ± 16.3 | 2.248 | 0.121 |

Notes: Means are presented followed by standard deviations

BDI: Beck Depression Inventory; BAI: Beck Anxiety Inventory; CFQ: Cognitive Failure Questionnaire; CTx+: Patients Treated with Chemotherapy; CTx-: Patients Not Treated with Chemotherapy; HC: Healthy Control

Table 3
Neurocognitive assessment before and after chemotherapy

| Domain/Test | CTx + (n = 13) | | | CTx - (n = 9) | | | F |
|--|----------------|--------------------|---------|---------------|--------------------|-------|----------|
| | baseline | 3 months follow-up | p | baseline | 3 months follow-up | p | |
| Attention and concentration | | | | | | | |
| Digit Span Forward | 10.8 ± 3.0 | 10.2 ± 3.2 | 0.407 | 9.2 ± 2.3 | 9.9 ± 1.9 | 0.322 | 0.863 |
| Digit Span Backward | 11.3 ± 3.3 | 10.9 ± 3.5 | 0.539 | 10.6 ± 2.1 | 10.3 ± 2.3 | 0.520 | 0.419 |
| Digit span total | 11.1 ± 3.1 | 11.2 ± 3.0 | 0.711 | 9.6 ± 2.1 | 9.9 ± 1.9 | 0.576 | 0.491 |
| Spatial span forward | 36.0 ± 33.8 | 41.6 ± 33.0 | 0.362 | 27.1 ± 32.7 | 22.6 ± 25.6 | 0.474 | 0.155 |
| Spatial span backward | 79.5 ± 14.5 | 72.4 ± 20.3 | 0.260 | 69.1 ± 26.6 | 71.3 ± 28.6 | 0.776 | 0.020* |
| Memory | | | | | | | |
| Rey-Kim memory quotient, | 102.5 ± 14.1 | 108.2 ± 10.3 | 0.131 | 108.7 ± 12.0 | 110.6 ± 11.7 | 0.326 | 0.072 |
| AVLT-sum | 10.4 ± 3.0 | 11.6 ± 1.8 | 0.220 | 12.1 ± 3.6 | 11.5 ± 2.6 | 0.310 | 0.632 |
| AVLT-delayed recall | 9.5 ± 2.6 | 10.2 ± 2.1 | 0.248 | 11.0 ± 2.2 | 11.9 ± 2.0 | 0.159 | 0.069 |
| AVLT-delayed recognition | 9.6 ± 3.7 | 10.4 ± 3.5 | 0.117 | 11.0 ± 2.7 | 12.8 ± 2.5 | 0.068 | 0.011* |
| KCFT copy (ageSS) | 14.7 ± 1.8 | 14.3 ± 2.1 | 0.910 | 14.3 ± 5.1 | 14.6 ± 2.0 | 0.563 | 0.927 |
| KCFT immediate recall (ageSS) | 13.1 ± 3.7 | 14.2 ± 2.0 | > 0.999 | 14.3 ± 1.9 | 14.3 ± 1.8 | 0.145 | 0.305 |
| KCFT delayed recall (ageSS) | 12.9 ± 3.6 | 14.5 ± 1.9 | 0.674 | 13.7 ± 2.3 | 14.0 ± 2.0 | 0.116 | 0.150 |
| Executive Function | | | | | | | |
| STROOP (%) | 56.0 ± 41.1 | 48.2 ± 37.6 | 0.097 | 56.2 ± 37.3 | 60.4 ± 34.2 | 0.631 | < 0.001* |
| CTx+: Patients Treated with Chemotherapy; CTx-: Patients Not Treated with Chemotherapy; AVLT: Auditory Verbal Learning Test; KCFT: Korean complex figure test; ageSS: age corrected scaled scores; | | | | | | | |

Neurocognitive Results

We compared the neurocognitive results of the CTx + group and the CTx- group (Table 2). Repeated-measures ANOVA demonstrated significant between-group differences over time in the spatial span backward test ($p = 0.020$), the auditory verbal learning test (delayed recognition, $p = 0.001$) and the stroop test ($p < 0.001$).

Neuroimaging Analysis

VBM analysis

Comparing the CTx + group and the CTx- group, there was neither significant group difference nor group-by-time interaction.

Functional connectivity analysis

When seeding from the right and left hippocampus, there was no significant group difference of the functional connectivity between the CTx + group and the CTx- group. However, functional connectivity analysis showed significant group-by-time interaction in the anterior thalamus (Table 4, Fig. 2). Post-hoc analysis using ROIs of the hippocampus subfields showed significant group-by-time interaction of the left CA – anterior thalamus functional connectivity, the left subiculum – precuneus functional connectivity, and the right subiculum – paracentral gyrus functional connectivity (Table 5).

Table 4

Brain regions showing significant group by time interaction in the hippocampus-based functional connectivity analysis.

| Region | side | BA | K | T _{max} | Coordinates | | |
|--|-------|----|-----|------------------|-------------|-----|----|
| | | | | | x | y | z |
| Functional connectivity with left hippocampus | | | | | | | |
| Thalamus, anterior nuclei | Left | | 305 | 5.29 | -8 | -6 | -8 |
| | | | | 4.82 | -4 | -12 | 12 |
| | Right | | | 3.86 | 6 | -10 | 12 |

Table 5

Brain regions showing significant group by time interaction in the 6 hippocampal subfields-based functional connectivity analysis.

| Region | side | BA | K | T _{max} | Coordinates | | |
|--|-------|----|-----|------------------|-------------|-----|----|
| | | | | | x | y | z |
| Functional connectivity with left cornu ammonis | | | | | | | |
| Thalamus, anterior nuclei | Right | | 228 | 4.92 | 2 | -10 | 14 |
| Functional connectivity with left subiculum | | | | | | | |
| Precuneus | Left | 7 | 122 | 5.14 | -6 | -58 | 56 |
| Functional connectivity with right subiculum | | | | | | | |
| Paracentral gyrus | Left | 4 | 122 | 4.49 | -12 | -20 | 66 |
| | | | | 4.17 | -10 | -24 | 58 |

DTI analysis results

Compared to CTx- group, CTx + group patients showed decreased FA and increased MD in left hippocampus (Fig. 3).

Discussion

To our knowledge, this study is the first multimodal longitudinal magnetic resonance imaging study on chemotherapy-induced cognitive impairment in gastric cancer patients. In this prospective and longitudinal study, we identified that compared to CTx- group, CTx + group resulted in dysfunction in attention, memory, executive function in short term follow up 3 months after chemotherapy. Result of DTI analysis demonstrated change in white matter integrity in left hippocampus. Resting state fMRI analysis with hippocampus, key region of cognitive function, set as seed, identified alteration of left hippocampus – anterior thalamus connectivity in chemobrain. Moreover, additional analysis of subfields of hippocampus identified alteration of left CA – anterior thalamus connectivity. Through these findings, we were able to confirm evidence of neuropathological change in chemobrain and qualitatively different neural changes in CTx + group compared to CTx- group. However, VBM analysis resulted in no structural change.

Considering the divergence of opinion surrounding existence of chemobrain and questions such as “Is chemobrain a phenomenon that really exist?” in place, our finding has significant clinical meaning. Interestingly, results from structural analysis in our study shows no difference in hippocampal volume, but intrinsic hippocampal functional connectivity change and hippocampal microstructural abnormalities were identified in chemobrain. In existing cross-sectional researches on hippocampal volume change in chemobrain showed inconsistent finding according to time interval after chemotherapy with some reporting reduced total volume (20, 21, 50), and others reporting no change (51). Considering that

changes in white matter and functional connectivity precede structural change in brain, it can be assumed that the reason behind no change in hippocampal volume in chemobrain is because short-term acute impact was evaluated. Furthermore, as widely known, hippocampus is a key domain in cognitive function and a domain that is involved in pathogenesis of neurodegenerative disorder (52, 53). This finding that detected change in hippocampus is in line with recent researches of prodromal Alzheimer's dementia; it can be interpreted that compared volumetric analysis methods, DTI measures of the hippocampus results reflect more sensitive cognitive impairment in early stage (54, 55). In mild cognitive impairment, which is clinical surrogate marker of incipient Alzheimer's dementia, while findings regarding change in gray matter volume are still ambiguous and inconsistent (56), at the beginning stage of cognitive dysfunction such as MCI, DTI measures is being revealed as a very useful tool for detecting subtle ultrastructural brain tissue alteration before brain atrophy or neuronal degradation is identified as macroscopic level (57). Previous studies have shown that hippocampal MD is a better predictor in predicting progress from MCI to dementia than volume measures. The fact that findings shown in early stage of neurodegenerative disease was found in this research results suggests neurotoxicity of chemotherapy. Moreover, this suggest that we should more closely evaluate and continuously follow up with patients who underwent chemobrain symptoms for therapeutic intervention.

In particular, in this study, we were able to identify changes in DTI measures in left hippocampus. Hippocampal asymmetry in patients with Alzheimer's dementia has often been identified in earlier studies (58, 59). In addition, past studies have suggested that left hippocampus is more intimately involved in earlier stage of the process of neurodegenerative disorder than right hippocampus, and left hippocampus is potentially better neural biomarker for cognitive decline than right hippocampus (60). In the same vein, the results of this study show neural change that matches that of early stage of neurodegenerative disease, and more attention should be paid to changes in left hippocampus in the early stages of the chemobrain phenomenon.

Interestingly, through functional connectivity analysis, we were able to identify qualitatively different alteration of left hippocampus-anterior thalamus functional connectivity in CTx + group compared to CTx-group. Anterior thalamus is a pivotal area in memory and cognition, and hippocampal-anterior thalamic interconnection is an area that plays vital role in human memory and cognition (61). In addition, the fact that change in the connectivity of hippocampal CA (62) and thalamus, which are known to be initially affected by neurodegenerative disorder such as Alzheimer's dementia, suggests that neural change due to chemobrain is similar to neural change due to early stage of neurodegenerative disorder. Therefore, in the future, study based on long term follow up of chemobrain should be carried out to study how resting state functional connectivity changes as chemobrain progresses.

In this study, we have identified that adjuvant chemotherapy on gastric cancer patient adjuvant chemotherapy has an effect on dysfunction of attention, memory, executive function according to objective neurocognitive test. As it has been known thus far, past studies show inconsistent result on cognitive impairment after chemotherapy due to reasons such as variability in study design and choice of comparison group (63). Moreover, reviewing previous studies, we found that there are still many

arguments regarding which domain's cognitive function chemobrain affects (64). This study has its strength because we enrolled subjects with normal cognitive functions in their 50 s who had completed formal education in order to exclude factors such as age and cognitive reserve that can affect cognitive function. As such, based on our findings, cognitive impairment affects attention, memory, and executive function of gastric cancer patients after chemotherapy. Therefore, it is important that chemobrain symptoms after chemotherapy that are directly related to patient's quality of life should be evaluated and treated early.

There are several limitations in this study. This study was conducted with small sample size due to difficulty in gathering cancer patients as participants. This might be why we found no significant correlations between the neuroimaging analyses measures (regional connectivity strengths and DTI measures) and results of neurocognitive tests. Another limitation is that follow-up period was not long enough. Therefore, if further study is conducted with larger study population by longer follow-up can identify how cognitive impairment changes and furthermore how neural change appears, it should be more helpful to understand underlying mechanism of chemobrain.

To our knowledge, this is the first longitudinal neuroimaging study on the effect of chemotherapy in gastric cancer patients. Our study shows adjuvant chemotherapy can cause decline in attention, memory and executive function of gastric cancer patients, accompanied by underlying neural change. Our study offers further evidence for the prevailing notion of cognitive alterations in patients after chemotherapy. Although basis underlying chemobrain is not clearly and universally explained, results from studies up to now present hypothesis that pathological processes and clinical presentation of chemobrain is ultimately similar disease as age-related neurodegenerative disorder including mild cognitive impairment and Alzheimer's disease (64). Through looking also into studies on neurodegenerative disease including mild cognitive impairment and Alzheimer's disease, we confirmed hippocampal abnormalities in chemobrain. Result from this study helps in viewing underlying basis of chemobrain at a new angle and puts emphasis in importance of continuous assessment and intervention. In the future, longitudinal studies should be made with homogenous and larger sample of patients. These studies will deepen our understanding of underlying mechanism of chemobrain and will have significance by enabling more effective therapeutic intervention for patients.

Conclusions

This is the first longitudinal neuroimaging study on chemobrain in male gastric cancer patients. Following the findings from this study indicating that clinical presentation and neuropathological processes centered on hippocampus of chemobrain is ultimately similar disease as age-related neurodegenerative disorder.

Declarations

Ethics approval and consent to participate

This prospective study was approved by the Institutional Review Board of Severance Hospital, and informed written consent was obtained from all subjects(patients) before each procedure in this study.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was supported by health fellowship foundation

Authors' contributions

All authors contributed to the study conception and design. Material preparation and data collection were performed by Kyung Ran Kim, and analysis were performed by Jaeun Ahn, DeokJong Lee and Young-Chul Jung. The first draft of the manuscript was written by Jaeun Ahn and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Berger AM, Shuster JL, Von Roenn JH. Principles and practice of palliative care and supportive oncology: Lippincott Williams & Wilkins; 2007.
2. Cull A, Hay C, Love S, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? *British journal of cancer*. 1996;74(10):1674.
3. Ahles TA, Root JC, Ryan EL. Cancer-and cancer treatment–associated cognitive change: An update on the state of the science. *J Clin Oncol*. 2012;30(30):3675.
4. Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. *Annu Rev Med*. 1983;34(1):35–46.
5. de Ruiten MB, Reneman L, Boogerd W, Veltman DJ, Van Dam FS, Nederveen AJ, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. *Hum*

- Brain Mapp. 2011;32(8):1206–19.
6. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. *Curr Neurol Neurosci Rep.* 2012;12(3):267–75.
 7. Koppelmans V, Vernooij MW, Boogerd W, Seynaeve C, Ikram MA, Breteler MM, et al. Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. *J Clin Oncol.* 2015;33(6):588–93.
 8. Simó M, Rifà-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. *Neuroscience Biobehavioral Reviews.* 2013;37(8):1311–21.
 9. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. *Cancer.* 2007;109(1):146–56.
 10. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. *Breast cancer research treatment.* 2010;123(3):819–28.
 11. Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. *J Clin Oncol.* 2011;30(3):274–81.
 12. Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Stock, Jvd, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. *Hum Brain Mapp.* 2011;32(3):480–93.
 13. Feng Y, Tuluhong D, Shi Z, Zheng LJ, Chen T, Lu GM, et al. Postchemotherapy hippocampal functional connectivity patterns in patients with breast cancer: a longitudinal resting state functional MR imaging study. *Brain imaging and behavior.* 2019:1–12.
 14. ELBeltagy M, Mustafa S, Umka J, Lyons L, Salman A, Tu C-YG, et al. Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. *Behav Brain Res.* 2010;208(1):112–7.
 15. Lyons L, ELBeltagy M, Bennett G, Wigmore P. Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. *PloS one.* 2012;7(1).
 16. Acharya MM, Martirosian V, Chmielewski NN, Hanna N, Tran KK, Liao AC, et al. Stem cell transplantation reverses chemotherapy-induced cognitive dysfunction. *Cancer research.* 2015;75(4):676–86.
 17. Christie L-A, Acharya MM, Parihar VK, Nguyen A, Martirosian V, Limoli CL. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. *Clinical cancer research.* 2012;18(7):1954–65.
 18. Oz M, Atalik KEN, Yerlikaya FH, Demir EA. Curcumin alleviates cisplatin-induced learning and memory impairments. *Neurobiol Learn Mem.* 2015;123:43–9.
 19. Ramalingayya GV, Cheruku SP, Nayak PG, Kishore A, Shenoy R, Rao CM, et al. Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats.

- Drug design, development and therapy. 2017;11:1011.
20. Apple AC, Ryals AJ, Alpert KI, Wagner LI, Shih P-A, Dokucu M, et al. Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. *NeuroImage: Clinical*. 2017;14:685–91.
 21. Cheng H, Li W, Gong L, Xuan H, Huang Z, Zhao H, et al. Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors. *Scientific reports*. 2017;7:45135.
 22. Squire LR, Ojemann JG, Miezin FM, Petersen SE, Videen TO, Raichle ME. Activation of the hippocampus in normal humans: a functional anatomical study of memory. *Proceedings of the National Academy of Sciences*. 1992;89(5):1837-41.
 23. Richard GR, Titiz A, Tyler A, Holmes GL, Scott RC, Lenck-Santini PP. Speed modulation of hippocampal theta frequency correlates with spatial memory performance. *Hippocampus*. 2013;23(12):1269–79.
 24. Gordon BA, Shelton JT, Bugg JM, McDaniel MA, Head D. Structural correlates of prospective memory. *Neuropsychologia*. 2011;49(14):3795–800.
 25. Mueller SG, Schuff N, Yaffe K, Madison C, Miller B, Weiner MW. Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer's disease. *Hum Brain Mapp*. 2010;31(9):1339–47.
 26. Jung K-W, Won Y-J, Kong H-J, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. *Cancer research treatment: official journal of Korean Cancer Association*. 2019;51(2):417.
 27. Oh C-M, Won Y-J, Jung K-W, Kong H-J, Cho H, Lee J-K, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. *Cancer research treatment: official journal of Korean Cancer Association*. 2016;48(2):436.
 28. Ahles TA, Root JC, Ryan EL. Cancer- and Cancer Treatment–Associated Cognitive Change: An Update on the State of the Science. *J Clin Oncol*. 2012;30(30):3675–86.
 29. Etemadi A, Safiri S, Sepanlou SG, Ikuta K, Bisignano C, Shakeri R, et al. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. *The Lancet Gastroenterology Hepatology*. 2020;5(1):42–54.
 30. Dhobi MA, Wani KA, Parray FQ, Wani RA, Wani ML, Peer G, et al. Gastric cancer in young patients. *International journal of surgical oncology*. 2013;2013.
 31. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. *Breast cancer research treatment*. 2008;110(1):143–52.
 32. Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. *Cancer*. 2007;109(9):1905–13.
 33. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. *Current oncology reports*. 2012;14(1):48–54.

34. Go PH, Klaassen Z, Meadows MC, Chamberlain RS. Gastrointestinal cancer and brain metastasis. *Cancer*. 2011;117(16):3630–40.
35. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. *Journal of biology*. 2008;7(4):12.
36. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The cognitive failures questionnaire (CFQ) and its correlates. *British journal of clinical psychology*. 1982;21(1):1–16.
37. Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio. 1996;78(2):490–8.
38. Steer RA, Beck AT. Beck Anxiety Inventory. 1997.
39. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV axis I disorders. New York: New York State Psychiatric Institute; 1995.
40. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage*. 2007;38(1):95–113.
41. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*. 2002;15(1):273–89.
42. Eickhoff SB, Stephan KE, Mohlberg H, Grefkes C, Fink GR, Amunts K, et al. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. *Neuroimage*. 2005;25(4):1325–35.
43. Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. *Brain connectivity*. 2012;2(3):125–41.
44. Leemans A, Jeurissen B, Sijbers J, Jones D, editors. ExploreDTI: a graphical toolbox for processing, analyzing, and visualizing diffusion MR data. *Proc Intl Soc Mag Reson Med*; 2009.
45. Leemans A, Jones DK. The B-matrix must be rotated when correcting for subject motion in DTI data. *Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine*. 2009;61(6):1336–49.
46. Tax CM, Otte WM, Viergever MA, Dijkhuizen RM, Leemans A. REKINDLE: robust extraction of kurtosis INDices with linear estimation. *Magn Reson Med*. 2015;73(2):794–808.
47. Veraart J, Sijbers J, Sunaert S, Leemans A, Jeurissen B. Weighted linear least squares estimation of diffusion MRI parameters: strengths, limitations, and pitfalls. *Neuroimage*. 2013;81:335–46.
48. Rohlfing T, Zahr NM, Sullivan EV, Pfefferbaum A. The SRI24 multichannel atlas of normal adult human brain structure. *Hum Brain Mapp*. 2010;31(5):798–819.
49. Klein S, Staring M, Murphy K, Viergever MA, Pluim JP. Elastix: a toolbox for intensity-based medical image registration. *IEEE Trans Med Imaging*. 2009;29(1):196–205.
50. Bergouignan L, Lefranc JP, Chupin M, Morel N, Spano JP, Fossati P. Breast cancer affects both the hippocampus volume and the episodic autobiographical memory retrieval. *PloS one*. 2011;6(10).
51. Eichbaum MH, Schneeweiss A, Sohn C. Smaller regional volumes of gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. *Cancer*.

- 2007;110(1):224–5.
52. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. 2008.
 53. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging*. 1997;18(4):351–7.
 54. Müller MJ, Greverus D, Weibrich C, Dellani PR, Scheurich A, Stoeter P, et al. Diagnostic utility of hippocampal size and mean diffusivity in amnesic MCI. *Neurobiol Aging*. 2007;28(3):398–403.
 55. Carlesimo GA, Cherubini A, Caltagirone C, Spalletta G. Hippocampal mean diffusivity and memory in healthy elderly individuals. A cross-sectional study. 2010;74(3):194–200.
 56. Van Petten C. Relationship between hippocampal volume and memory ability in healthy individuals across the lifespan: review and meta-analysis. *Neuropsychologia*. 2004;42(10):1394–413.
 57. Fellgiebel A, Wille P, Müller MJ, Winterer G, Scheurich A, Vucurevic G, et al. Ultrastructural Hippocampal and White Matter Alterations in Mild Cognitive Impairment: A Diffusion Tensor Imaging Study. *Dement Geriatr Cogn Disord*. 2004;18(1):101–8.
 58. Barnes J, Scahill RI, Schott JM, Frost C, Rossor MN, Fox NC. Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study. *Dement Geriatr Cogn Disord*. 2005;19(5–6):338–44.
 59. Geroldi C, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, et al. Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. *J Neurol Neurosurg Psychiatry*. 2000;68(1):93–6.
 60. Eckerström C, Olsson E, Borga M, Ekholm S, Ribbelin S, Rolstad S, et al. Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: The Göteborg MCI study. *J Neurol Sci*. 2008;272(1):48–59.
 61. Aggleton JP, O'Mara SM, Vann SD, Wright NF, Tsanov M, Erichsen JT. Hippocampal–anterior thalamic pathways for memory: uncovering a network of direct and indirect actions. *Eur J Neurosci*. 2010;31(12):2292–307.
 62. Atienza M, Atalaia-Silva KC, Gonzalez-Escamilla G, Gil-Neciga E, Suarez-Gonzalez A, Cantero JL. Associative memory deficits in mild cognitive impairment: The role of hippocampal formation. *NeuroImage*. 2011;57(4):1331–42.
 63. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. *J Clin Oncol*. 2012;30(30):3675–86.
 64. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. *J Clin Oncol*. 2010;28(29):4434.

Figures




Figure 1

Flowchart of the study Note: K-WAIS-IV: Korean Wechsler Adult Intelligence Scale-IV; MRI: Magnetic resonance imaging




Figure 2

When seeding from the left hippocampus, functional connectivity analysis showed significant group-by-time interaction in the anterior thalamus (red).




Figure 3

Decreased mean FA and increased mean MD among CTx+ group at 3 months follow up as compared to CTx+ group at baseline in left hippocampus. Notes: CTx+: Patients Treated with Chemotherapy; CTx-: Patients Not Treated with Chemotherapy; FA: fractional anisotropy; MD: mean diffusivity